{"schema_version":"secwatch.filing_event.v1","accession":"0001847367-25-000039","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.334518+00:00","generated_at":"2026-05-17T13:59:41.662715+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alumis Q2 net income $59.3M (incl. $187.9M merger gain); Phase 3 psoriasis & Phase 2b SLE enrollment complete","bullets":["Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.","Phase 3 ONWARD trials (psoriasis) fully enrolled; topline data expected early Q1 2026.","Phase 2b LUMUS trial (SLE) fully enrolled with 408 patients; topline data expected Q3 2026.","Completed merger with ACELYRIN, adding $382.6M cash; total merger-related expenses of $26.8M in Q2.","R&D expenses $108.8M (up from $48.6M); G&A $34.5M (up from $7.6M) driven by merger costs and clinical acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001847367-25-000039","json":"https://secwatch.observer/filing/0001847367-25-000039.json","markdown":"https://secwatch.observer/filing/0001847367-25-000039.md","text":"https://secwatch.observer/filing/0001847367-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/0001847367-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:59:41.662715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}